Alle Storys
Folgen
Keine Story von Intercell AG mehr verpassen.

Intercell AG

euro adhoc: Intercell AG
Joint Ventures/Cooperation/Collaboration
Intercell receives EUR 1 million milestone payment from partner sanofi pasteur for bacterial vaccine candidate

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
09.01.2006
Vienna (Austria), January 9, 2006 - Intercell AG (VSE, "ICLL")
announced today that the next milestone within the collaboration with
sanofi pasteur for the development of a bacterial vaccine has
successfully been achieved. This significant progress within the
preclinical development of a bacterial vaccine candidate resulted in
another milestone payment of EUR 1 million for Intercell.
In July 2005, sanofi pasteur exercised its option on exclusive
worldwide commercial rights on certain bacterial vaccine antigens,
which have been identified by Intercell’s Antigen Identification
Program. Over the entire term of the agreement, Intercell will be
entitled to further milestone based license payments totaling to
about EUR 20 million, as well as royalties on future net sales. The
EUR 1 million milestone payment received now will be accounted for as
revenue of the financial year 2005.
The vaccine candidate, which has the potential to address an
important unmet medical need in the field of infectious diseases, was
licensed from Intercell under a collaboration and license option
agreement signed in December 2003. The parties have agreed
confidentiality on the indication.
"We’re pleased about this significant progress in the development of
a bacterial vaccine candidate fully derived from our proprietary
Antigen Identification Program within our collaboration with sanofi
pasteur," commented Gerd Zettlmeissl, CEO of Intercell AG. "This
emphasizes once again the value and potential of our technologies for
the development of novel vaccines."
This communication expressly or implicitly contains certain
forward-looking statements concerning Intercell AG and its business.
Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Intercell AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Intercell AG is providing this communication as of this date and does
not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.
end of announcement                               euro adhoc 09.01.2006 07:10:55

Further inquiry note:

Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market

Weitere Storys: Intercell AG
Weitere Storys: Intercell AG